Pacritinib Market In Global
Pacritinib is an orally bioavailable inhibitor of Janus kinase 2 (JAK2) and the JAK2 mutant JAK2V ... Read More
2,3,4,6-Tetrakis-O-Trimethylsilyl-D-Gluconolactone (CAS 32384-65-9) is a synthetic building block which has been used to prepare C-glucosides via the nucleophilic addition of a suitably functionalised aryllithium reagent, followed by a triethylsilane reduction.
This report contains market size and forecasts of 2,3,4,6-Tetrakis-O-Trimethylsilyl-D-Gluconolactone in global, including the following market information:
Global 2,3,4,6-Tetrakis-O-Trimethylsilyl-D-Gluconolactone Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global 2,3,4,6-Tetrakis-O-Trimethylsilyl-D-Gluconolactone Market Sales, 2017-2022, 2023-2028, (Kg)
Global top five 2,3,4,6-Tetrakis-O-Trimethylsilyl-D-Gluconolactone companies in 2021 (%)
The global 2,3,4,6-Tetrakis-O-Trimethylsilyl-D-Gluconolactone market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Min Purity Less Than 98% Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of 2,3,4,6-Tetrakis-O-Trimethylsilyl-D-Gluconolactone include Clearsynth, Biosynth Carbosynth, Taiclone, Toronto Research Chemicals, Pharmaffiliates, CarboMer, Apollo Scientific, Cato Research Chemicals and Novachemistry, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the 2,3,4,6-Tetrakis-O-Trimethylsilyl-D-Gluconolactone manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global 2,3,4,6-Tetrakis-O-Trimethylsilyl-D-Gluconolactone Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (Kg)
Global 2,3,4,6-Tetrakis-O-Trimethylsilyl-D-Gluconolactone Market Segment Percentages, by Type, 2021 (%)
Min Purity Less Than 98%
Min Purity 98%-99%
Min Purity More Than 99%
Global 2,3,4,6-Tetrakis-O-Trimethylsilyl-D-Gluconolactone Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (Kg)
Global 2,3,4,6-Tetrakis-O-Trimethylsilyl-D-Gluconolactone Market Segment Percentages, by Application, 2021 (%)
Research
Medical
Global 2,3,4,6-Tetrakis-O-Trimethylsilyl-D-Gluconolactone Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (Kg)
Global 2,3,4,6-Tetrakis-O-Trimethylsilyl-D-Gluconolactone Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies 2,3,4,6-Tetrakis-O-Trimethylsilyl-D-Gluconolactone revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies 2,3,4,6-Tetrakis-O-Trimethylsilyl-D-Gluconolactone revenues share in global market, 2021 (%)
Key companies 2,3,4,6-Tetrakis-O-Trimethylsilyl-D-Gluconolactone sales in global market, 2017-2022 (Estimated), (Kg)
Key companies 2,3,4,6-Tetrakis-O-Trimethylsilyl-D-Gluconolactone sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Clearsynth
Biosynth Carbosynth
Taiclone
Toronto Research Chemicals
Pharmaffiliates
CarboMer
Apollo Scientific
Cato Research Chemicals
Novachemistry
Energy Chemical.
J&K Scientific
Pacritinib is an orally bioavailable inhibitor of Janus kinase 2 (JAK2) and the JAK2 mutant JAK2V ... Read More
Upadacitinib is a selective JAK inhibitor under the development of AbbVie.ABT-494 is nearly 74 fo ... Read More
Momelotinib, an aminopyrimidine derivative discovered by high-throughput enzyme and cell-based sc ... Read More
Ozanimod is a selective, orally available modulator of the sphingosine-1-phosphate (S1P) receptor ... Read More